Tarsus Pharmaceuticals, Inc.
TARS
$59.83
$0.180.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 535.08M | 451.36M | 366.10M | 295.52M | 233.67M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 535.08M | 451.36M | 366.10M | 295.52M | 233.67M |
| Cost of Revenue | 107.13M | 95.01M | 87.84M | 78.62M | 72.11M |
| Gross Profit | 427.95M | 356.35M | 278.26M | 216.90M | 161.56M |
| SG&A Expenses | 478.76M | 427.32M | 365.67M | 314.95M | 270.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 585.89M | 522.33M | 453.51M | 393.57M | 342.84M |
| Operating Income | -50.81M | -70.97M | -87.41M | -98.05M | -109.17M |
| Income Before Tax | -43.85M | -64.36M | -81.16M | -91.99M | -104.94M |
| Income Tax Expenses | 4.41M | 2.06M | -- | -- | -- |
| Earnings from Continuing Operations | -48.27 | -66.42 | -81.16 | -91.99 | -104.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.27M | -66.42M | -81.16M | -91.99M | -104.94M |
| EBIT | -50.81M | -70.97M | -87.41M | -98.05M | -109.17M |
| EBITDA | -49.02M | -69.15M | -85.61M | -96.42M | -107.75M |
| EPS Basic | -1.13 | -1.61 | -2.01 | -2.33 | -2.73 |
| Normalized Basic EPS | -0.59 | -0.93 | -1.23 | -1.42 | -1.64 |
| EPS Diluted | -1.13 | -1.61 | -2.01 | -2.33 | -2.73 |
| Normalized Diluted EPS | -0.59 | -0.93 | -1.23 | -1.42 | -1.64 |
| Average Basic Shares Outstanding | 170.71M | 167.10M | 162.87M | 158.65M | 154.11M |
| Average Diluted Shares Outstanding | 170.71M | 167.10M | 162.87M | 158.65M | 154.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |